Ann: Sensera completes A$2.5m private placement, page-174

Great stuff @duboo88 !

I'm hoping that part of the delay for NanoDX is that given the timing of market entry, that they are moving straight to a Mulitiplex test, testing for Sars-Cov-2, Influenza A and Inflluenza B simultaneously. This is the way testing is moving in the USA, and likely to be the recommended by the CDC this winter season in the Northern Hemisphere.

I did notice in the release around licencing IBM IP there was constant referral to influenza as one of the tests that can be performed.
It does mean that the NanoDX system would need to test & differentiate against several biomarkers at once. I can only imagine this would introduce a whole new level of complexity to the system design & production, and a challenge at the microfuidics level as well. If the EUA submission is for a Multiplex test, we will have jumped to the front of the testing cue ... and @Dubbo88 may need to look for a 2nd foundry to licence !

IMO.
GLTAH